Zydus will enrol over 1,000 subjects across multiple clinical study sites in India
Zydus has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world’s third worst-hit nation.
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said in Bengaluru.
In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.
- Advertisement -